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Summary 
The aim of this study was to provide proof-of-concept for quantitative and qualitative 
label-free detection of immune complexes through myeloid cells with imaging surface 
plasmon resonance. Surface plasmon resonance imaging was first applied to monitor 
the binding of human sera from healthy and RA patients to immobilised citrullinated 
RA specific peptide antigens, HCP2 and VCP2. Next, the binding of monocytoid cell 
line U937 to the resulting immune complexes on the sensor surface was monitored. 
As control, binding of U937 was monitored to IgG subclasses simultaneously. Cell 
response results were compared to results of CCP2 ELISA, clinical RA diagnosis and 
antigen specific antibody distribution of the samples. Human IgG3 triggered the most 
pronounced response followed by IgG1 and IgG4, while IgG2 did not result in U937 
cell binding. Serum samples obtained from RA patients resulted in significantly 
increased cell response to VCP2 compared to healthy controls. The strength of cell 
response towards VCP2-immune complexes showed significant correlation with 
levels of antigen specific IgA, IgG and IgG3. Cellular responses on VCP2 immune 
complexes showed significant association with both CCP2-based serological 
positivity and EULAR criteria-based clinical RA diagnosis. Immunoglobulin-triggered 
binding of monocytoid cells can be monitored using a label-free multiplex technology. 
Since these binding events are presumably initiated by Fc receptors, the system 
provides a tool for biological detection of autoantibodies with diagnostic value, here 
exemplified by anti-citrullinated antibodies. This provides added information to 
antibody levels, as interaction with Fc-receptor-expressing cells are also affected by 
post-translational modification of the immunoglobulins. 
Key words: imaging SPR, IgG, ACPA, Fc Receptor, monocyte 
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Introduction 
Detection of antigen-specific antibody reactivity is of great interest for the diagnosis of 
various pathogenic conditions. Most commonly this is obtained by measuring 
antibodies in biological samples, such as from blood serum by ELISA [1] or 
immunofluorescence based tests [2]. The results obtained represent a simplified view 
of the immunological reactivity - as only isotype and or IgG subclass of the antigen 
specific antibody is reported as a biomarker of a given pathological state.  
However, the diversity of antigen specific reactivity is much more complex as the 
magnitude of the effector functions is dependent on the combination of isotypes and 
subclasses involved and the antibody levels mounted. The antibody glycosylation in 
the conserved N-linked glycosylation site at position 297 in the Fc portion in IgG and 
IgE can also be varied and affects binding affinities to Fc-receptors [3-5]. IgG and 
IgM responses can also lead to activation of the complement system [6], and further 
opsonisation of innate molecules such as pentraxins [7] can also influence the 
outcome of the immune response. The resulting immune complex (IC) will eventually 
lead to differential engagement of Fc- and complement receptors on myeloid effector 
cells. Thus the final makeup of IC determines the type and magnitude of the resulting 
inflammatory response [8]. 
In our previous work we have shown that ICs can be detected through the binding of 
fluorescently labelled U937 histiocytic lymphoma cells [9] to spotted immunoglobulins 
and antigens (after serum treatment) on nitrocellulose based microarrays [10]. U937 
cells express the IgA receptor (FcαR), but also the IgG receptors (FcγR) FcγRIa and 
FcγRIIa (CD64 and CD32, respectively) [11]. Their different affinities towards the 
human IgG subclasses [12] resulted in distinct adhesion profiles depending on the 
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IgG subclass, which was also affected by complement deposited by these IgG 
antibodies.  
In the current study we report a novel approach where immunological reactivity of 
serum samples is detected directly and in real-time by the adhesion of 
immunologically relevant effector cells to immune complexes in a label-free manner 
using surface plasmon resonance (SPR). Besides the typical measurements such as 
determination of affinity, specificity and binding kinetics, we and others have shown 
that cells can also be detected [13-17]. This has been achieved by coupling cellular 
ligands (e.g. cell surface antigen specific antibodies) covalently onto the sensor and 
cells are used as analytes, as presented for T- and B-lymphocytes [14]  and breast 
cancer cell lines [17], or by monitoring morphological changes in real-time upon 
activation [18, 19].  
Rheumatoid Arthritis (RA) is an autoimmune disease that is characterized by 
autoantibody production [20]. These autoantibodies are categorized to two main 
groups: rheumatoid factors and anti-citrullinated protein antibodies (ACPA). 
Rheumatoid factors (RF) are usually IgM antibodies directed against the constant 
region of IgG. Tests determining IgM RF levels have a relatively low specificity (85%), 
but are routinely used for their sensitivity (69%)[21]. RF positivity was found to be 
positively correlated with the subsequent onset of RA in a recent prospective study 
[22] and was reported to have a higher affinity to hypogalactosylated IgG [23]. 
Moreover ACPA were also found to be hypogalactosylated compared to total IgG1 
[24, 25]. ACPA positivity of multiple isotypes precedes the onset of the clinical 
symptoms in RA[24] and the presence of such autoantibodies is now included in the 
Classification Criteria of RA [26]. ACPA testing is done routinely with Cyclic 
Citrullinated Peptide (CCP) ELISA [27]. With this technique isotype distribution can 
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be monitored as well, however no correlations have been found with disease activity. 
Importantly, ACPA–triggered, FcγR mediated inflammatory cytokine production by 
macrophages has been demonstrated, indicating a pathogenic role for these 
antibodies [28]. Detection of ACPA by SPR Imaging have also been established 
earlier, demonstrating that bio-molecular interactions between citrullinated peptides 
and autoantibodies can be monitored with great precision in real time using this 
technique [29].  
In this study we tested whether the ICs formed on sensor surface with RA specific 
antigens trigger adhesion of U937 cells. We then tested if this quantitative information 
on both specific antibodies and their capacity to trigger cellular activation obtained 
simultaneously in a label-free manner yields useful information on the patient´s 
clinical state.  
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Materials and Methods 
Cell culture 
Human premonocytic cell line U937 was cultured in RPMI-1640 medium (Gibco) 
supplemented with 10% FCS, 2 mM glutamine, penicillin (100 U/ml) and streptomycin 
(100 µg/ml) and was maintained at 37°C in a humidified atmosphere of 5% carbon 
dioxide. 
Measurement of U937 binding to IgG subclasses and on-sensor formed 
complexes with IBIS MX96 
The IBIS MX96 (Ibis Technologies, Enschede, The Netherlands) surface plasmon 
resonance imager (SPRi) has several advantages as an array with up to 96, but more 
conveniently 48, different molecules can be coupled to the sensor surface, monitoring 
cellular interaction to all of them in parallel in real-time. The microfluidic system of 
IBIS MX96 with the sensor surface on the bottom facing upwards in the optical 
imaging chamber enables the application and gravitational sedimentation of cells as 
demonstrated for red blood cell typing and detection of cell antigens on adherent 
cells [16, 17]. Human IgG1-4 (Sigma) were spotted in 10 mM acetate buffer, pH 5.4 in 
replicates to pre-activated Easy2Spot P-type chips (Ssens, Enschede, The 
Netherlands) using a Continuous Flow Microspotter (Wasatch Microfluidics, Salt Lake 
City, USA). 100 nM BSA in 10 mM sodium acetate buffer, pH 4 was spotted as 
negative control and acetate buffer as reference. Multiple Antigenic Peptides (MAPs): 
Histone derived HCP2 [30], and Epstein-Barr virus derived VCP2 [31] (from Toscana 
Biomarkers Srl) were spotted at 10 mM and 1 mM spots in replicates in 10 mM 
acetate buffer, pH 5 and 10 mM MES buffer, pH 6.0 respectively with IgG1 and 3 as 
positive controls. The sensor was blocked with 1 mg/ml BSA in 10 mM sodium 
acetate buffer, pH 4 with 0,075% Tween-80 and then with 100 mM ethanolamine, 
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pH8 with 0.075% Tween-80. Injection of 50 nM anti-kappa-chain specific antibody 
(mouse anti-human Kappa UNLB, Southern Biotech, clone SB81a) was used to 
determine equal spotting concentration of the human IgG subclasses, identified as 
108 nM for IgG1, 125 nM for IgG2, 100 nM for IgG3 and 148 nM for IgG4. As system 
and sample buffer PBS with 0.1% BSA (PBS-BSA) was used. All materials including 
cells and serum samples were diluted in this buffer. For regeneration in between 
measurements 200 nM H3PO4 and 0.5% SDS was used in two cycles to regenerate 
the sensor surface. The temperature was set to 25°C. Each chip was not used for 
more than 14 runs. 
For testing serum- followed by U937-myeloid cell reactivity to the spotted antigenic 
peptides, first the baseline (0-300 sec) was set with system buffer. Then 100 µl 1:10 
diluted heat-inactivated serum was injected and the sample association took place for 
15 minutes under back-and-forth flow. This was followed by the dissociation phase 
with system buffer, under back and forth flow for 10 minutes. Next U937 cells (200 µl 
of 2*106/ml in PBS-BSA) were injected on the sensor surface and were incubated for 
15 minutes after stopping the flow, allowing cells to sediment and bind specific 
ligands. Changes in angular-shift were recorded to all spots in real time, monitoring 
both reactivity of sera and cells in corresponding phases of the measurement. 
 
Serum samples 
Serum samples from RA patients (n = 18) and control serum samples (n = 5) were 
obtained by venopuncture at University of Pécs and at University of Pisa and were 
stored at -70°C until use. The national ethics committee of Hungary and Italy gave 
their approval for conducting study with the following contract numbers, respectively: 
24973-1/2012/EKU (658/PI/2012.), 45066/2012. RA patients fulfilled the international 
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Rheumatoid arthritis classification criteria [26]. Serum samples were tested with anti-
CCP2 ELISA (InovaDiagnostics, California, USA), according to the manufacturer’s 
instructions. Heat-inactivation was carried out at 56°C for 30 minutes. 
 
Detection of HCP2 and VCP2 specific IgG subclasses in RA samples with 
ELISA 
96 well ELISA plates were coated overnight, 4°C with 5 µg/ml HCP2 and VCP2, 
diluted in carbonate-bicarbonate buffer pH 9.6 or PBS, respectively. After washing 
with PBS + 0.05% Tween-20 wells were blocked with PBS + 3% BSA for 1h room 
temperature (RT), samples were diluted 1:50 in PBS with 1% BSA and 0.05% 
Tween-20 and were incubated for 3h at on shaker, RT. Subclass specific biotinylated 
mouse anti-human antibodies (ahIgG1-b and 2b (BD Pharmingen), ahIgG3-b and 4-b 
(Southern Biotech)) were diluted 1:8000 in PBS-Tween and were incubated for 1h, 
RT. Biotinylated antibodies were detected with Streptavidin-HRPO (Sigma), diluted 
1:5000 in PBS-Tween, 1h, RT. After washing 1% TMB with 0.2% H2O2 in TMB buffer 
was added to each well. After 10 minutes 2N H2SO4 was added to each well to stop 
the reaction. Optical Density was recorded at 450 nm. Control measurements without 
serum samples were used to determine the background values, background 
subtracted values were analyzed. 
 
Statistical analysis 
Spearman rank correlations were calculated to compare IgG, IgA, IgM and IgG1-4 
and U937 and serum association signals on MAPs. Statistical differences in serum 
binding and cell adhesion during and following incubation of IgG subclasses and 
MAPs with healthy and RA sera were assessed by pairwise comparisons of relevant 
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groups using Mann-Whitney U test. To compare the results obtained by cell adhesion 
to MAPs following serum treatment and results of CCP2 tests and RA diagnosis by 
physician, Fisher’s exact test was used. Statistical tests were considered significant 
as follows: non-significant (n.s.) - p ≥ 0.05, * - p < 0.05, ** - p < 0.01 and *** - 
p < 0.001. 
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Results 
U937 cells bind to human IgG1, IgG3 and IgG4 but not to IgG2 
To simultaneously measure serum responses to antigens and cells we utilized a SPR 
biosensor system allowing monitoring of up to 48 interactions simultaneously on an 
array of covalently coupled ligands. While serum reaction can be easily detected by 
classical SPR, we and others have recently shown the IBIS MX96 system to be 
capable of red blood cells, platelets and tumour cell detection after gravity 
sedimentation[16, 17, 32] – but never to deposited ligands. To investigate if U937 
cells bind IgG in the IBIS, first we determined the coupling efficiency of each IgG 
subclass, using antibody against the light chain (anti-kappa monoclonal antibody) 
shared by all four IgG subclasses. At 100 Response Units (RUs) of each coupled IgG 
subclass, no significant differences were observed with the anti-kappa IgG 
suggesting equal coupling. Ten fold dilutions reduced this signal, particularly for 
IgG2, suggesting alternative configuration on the chip at lower densities (Figure 1A). 
No anti-kappa signal was detected when IgG were spotted at one RU. We then 
analysed the interaction between U937 cells with the IgG-coupled chips. After 
injection of the U937 cells, they were allowed to interact with the sensor surface by 
sedimentation after stopping the flow (Figure 1B). This resulted in specific interaction 
of the cells with IgG1, IgG3 and IgG4 compared to BSA, judged by the change in 
real-time angle-shift. We found that IgG3 was the most effective in triggering cell 
adherence, IgG1 and IgG4 were roughly half that effective, while IgG2 induced very 
little or no cell adherence. Interestingly this preference of IgG3 was so pronounced 
that even at the hundred-fold dilution (~1 nM) some of the spots gave similar 
response as the 100 RU (Figure 1C). Repeated measurements on a single chip 
indicated that quantitative measurements could be achieved between all spots within 
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a single cycle, and between cycles for up to 14 independent runs after repeated use 
and regenerations (Supplementary Figure 1). 
Sera of RA patients lead to myeloid cell detection of VCP2 
We next tested if serum-derived reactivity towards antigens can also be detected 
using myeloid cells as readout. To this end we compared the reactivity of sera from 
RA patients and normal healthy serum donors (NHS) towards the RA specific 
citrullinated MAPs: HCP2 and VCP2. As positive controls we spotted hIgG1 and IgG3 
at 100 and 10 nM spotting concentrations, and BSA and PBS as negative controls. 
Incubation of sera showed typical binding resembling antibody-antigen (ligand-
receptor) during the association and dissociation phase (left and middle sides of 
sensograms in Figure 2A, respectively, as summarized in the cartoon in Figure 2B). 
We noted that sera of RA patients showed significantly elevated serum-reactivity 
towards IgG1, consistent with increased levels of Rheumatoid factor in these patients 
(right side Figure 2A, and Figure 2C). Likewise, sera of RA patients showed a 
significantly increased serum response to HCP2 and VCP2 compared to NHS 
patients (Figures 2A and 2D).We then introduced the U937 cells, allowing them to 
interact with the immune complexes deposited on the sensor surface (right half of 
sensograms in Figure 2A as summarized Figure 2B). U937 cells reacted equally 
strong to IgG1 and IgG3 equipped control spots treated with NHS and RA sera 
(Figure 2A and E).  Although many NHS showed elevated serum binding to HCP2, 
these did not result in myeloid U937-binding (Figure 2A, D-F). Importantly, U937 cells 
reacted significantly stronger with RA-serum-treated VCP2 spots compared to NHS 
(Figure 2F). The cellular response to HCP2 was not significantly elevated compared 
to NHS, although RA samples tended to give stronger response. While for HCP2 no 
correlation was found between levels of serum and cell response, for VCP2, the 
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cellular response significantly correlated with the level of serum response measured 
in the same run, showing moderate association (Figure 2G).  
 VCP2-specific antibody responses correlated with cellular responses  
The ability of U937 cells to differentiate among patient sera raised the question 
whether it was associated to their antigen-specific antibody isotype and subclass 
composition. For both HCP2 and VCP2, specific antibodies of multiple subclasses 
were detectable in most of the higher responding samples and the subclasses-levels 
themselves showed strong correlations with each other (Supplementary Table 1). 
The same was true for the isotypes, with a strong significant correlation between the 
antigen specific IgA, IgG and IgM levels (Supplementary Table 2). VCP2 specific 
serum responses recorded on the IBIS chips correlated significantly with the IgG and 
IgA levels measured on antigen microarrays (see Supplementary Methods) and with 
levels of IgG1, IgG3 and IgG4 measured with ELISA, however no correlations were 
found in case of HCP2 (Supplementary Figure 2). 
The antigen specific IgG and IgA levels showed significant correlation with cellular 
response to VCP2, but not with IgM (Figure 3A). Looking closer at the IgG subclass 
responses, we found strong significant correlation between IgG3 levels with the 
U937-reactivity to serum opsonised VCP2-sensor chips (Figure 3B). No significant 
correlations were found between antibody levels and U937 reactivity for HCP2 
(Figure 3A-B).  
Cell response on VCP2 shows significant association with CCP2 positivity and 
RA diagnosis  
To evaluate its diagnostic performance, we compared the cellular responses towards 
the opsonised MAP biosensor with serological and clinical diagnostic RA criteria. For 
comparison of cellular responses, we categorized samples into positive and negative 
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sets based on cell response results, using the highest measured cell response value 
in the NHS group as a cut-off value. We then compared the cellular response to the 
results of CCP2 ELISA. While VCP2 cell responses showed significant association in 
both comparisons (Table 1), no significant association was observed for HCP2. By 
measuring cell responses to serum-opsonised VCP2 chip we could identify 11 out of 
12 seropositive (CCP2+) and 67% of clinically established RA patients. 
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Discussion 
In this work we examined the application of monocytic cell line U937 to detect 
immune complexes using label-free SPRi in real time as a potential method to 
evaluate the clinical relevance of humoral autoantibody formation. We found that 
immune complexes are formed on relevant RA antigens spotted on the biosensor 
surface, which are subsequently recognized by myeloid cells. The magnitude of the 
cellular recognition seemed to be associated with the quality of the deposited 
antibodies, and be related to clinical signatures in RA.  
Detection of immune complexes using cells has several advantages beyond 
serology. This is because serology alone does not give any information on the quality 
of the immune response besides isotype or subclass. Any additive qualitative 
information that affects recognition by effector cells is lost. This can be due to affinity 
of the antibodies involved, stoichiometry, or antibody Fc-glycosylation – all factors 
affecting binding to FcγR [5, 33-35].  
Using a label-free biosensor method for this task eliminates the need of excessive 
sample handling in the form of cellular labelling. By applying the antigens on a 
surface, as opposed to in solution, we potentially mimic surface exposed antigens 
which change the pathogenic autoantibody and Fc-receptor interactions from low-
affinity and low-avidity to high avidity interactions. This mimics the recognition of 
surface-deposited antibodies - more easily recognized by myeloid cells – which may 
also occur in vivo. However, using SPR for this application has not been widely 
applied so far due to several challenges not easily solved with most currently 
available SPR equipment.  Here, we utilized a system with reversed optics, allowing 
for sedimentation of the cells towards the sensor surface, equipped with up to 96 
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different antigens which can be monitored in parallel. During the process sera and 
cells are injected serially. After injection of the cells, they are allowed sediment onto 
the sensor surface, and then interact with molecules opsonised on the sensor 
surface, allowing adhesion of the cells, registered as change in the angle shift 
measured by classical SPR methods [16].  
First we looked at the cell adhesion to human IgG subclasses and found that the cells 
recognize and adhere to these molecules presumably through their FcγR. U937 cells 
express FcγRs: FcγRIIa, and FcγRI[36]. The high affinity FcγRI can bind IgG1, IgG3 
and IgG4 but not IgG2. U937 cells expresses the R131 variant of FcγRIIa [37], which 
binds most efficiently IgG1 and IgG3, slightly better than IgG4, and has minimal 
reactivity to  IgG2 [12, 38]. In addition, U937 cells may express the inhibitory FcγRIIb 
[39, 40], but this is still controversial [41].  FcγRIIb has the lowest affinity to IgG of all 
human FcγRs and binds all subclasses except IgG2 [12]. Binding of U937 cells to 
human IgG subclasses in SPRi measurements followed the pattern of the relative 
affinity of FcγRs expressed on U937 cells, favouring IgG3 over IgG1 and IgG4 and 
showing no or little reactivity to IgG2. This is in accordance with our previous results 
based on nitrocellulose based microarray experiments [10].  
Measurement of RA specific reactivity of sera by citrullin-arginin peptide pairs 
coupled to SPRi sensors have been demonstrated earlier [29], also with HCP2 and 
VCP2 peptides in a Biacore system [42]. In agreement with those studies, we also 
found patients sera react to these peptides in our biosensor setup. We then injected 
U937 cells and allowed them to interact with the opsonised sensor surface without 
flow. We observed a specific interaction of the U937 cells with the MAPs-sensor 
spots after opsonisation with reactive sera on-chip. Previous studies investigating 
anti-keratin antibodies [43], and later ACPA in samples from RA patients revealed 
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different isotype distribution when measured on different peptides, mostly with high 
IgG1-levels, frequent IgG4-positivity, but without IgG2 [43-47]. Class-switching is 
generally thought to develop before the onset of the specific spectra of symptoms 
characterizing RA[48]. Comparison of ACPA isotypes in samples from RA patients 
and their healthy relatives showed that unaffected relatives may also have  ACPA, 
most frequently IgG1 and IgA, while a more diverse isotype contribution was 
characteristic for RA symptoms [49]. The presence of five or more ACPA antibody 
types and high levels of total IgG anti-CCP2 were associated with more severe 
disease progression [44]. In general IgM, IgA and the IgG subclasses all seem to 
contribute to ACPA-mediated clinical symptoms, with the available data suggesting 
ACPA IgG being the most prominent disease inducer[44, 50, 51]. In agreement with 
this published literature, it was difficult to pinpoint a single isotype or IgG-subclass 
promoting the strongest cellular response, as all show underlying secondary 
correlations. Serum response measured on HCP2 significantly discriminated the RA 
and NHS group, yet this did not lead to a significant cell response. This may possibly 
be due to high concentrations of low affinity IgM outcompeting IgG. The deposited 
IgM would also not be expected to lead to cellular activation as no receptors for IgM 
have been described on U937 cells. This lack of correlation between serum response 
and antigen specific IgM possibly results from removal of low-affintiy IgM with 
thorough washing in our microarray protocol. However, VCP2 specific IgA, IgG and 
IgG3 levels did show strong correlations with cellular response, mirroring reported 
clinical associations [46, 52, 53]. For VCP2, serum and cell response showed 
significant correlation, which was not found for HCP2, suggesting qualitatively distinct 
set of antibodies recognizing these two antigens. The moderate association in case 
of VCP2 further supports the notion that cellular response, given a sufficient serum 
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response, is driven rather by the quality over the quantity of the reacting serum 
components. 
The present method shows that interactions of monocytoid cells with citrullinated 
peptides after incubation with patient sera is strongly associated with the diagnosis of 
RA and CCP positivity. Further development of the presented method, utilizing more 
target peptides and proteins in a single run should help us to determine antigen 
specific immune response in more detail. An added information would be acquired if 
the donors own cells could be used, as the response is also likely to be influenced by 
the polymorphism of FcγRs [38, 54]. Characterizing the effector function-triggered 
cell activation by serum antibodies on different antigens could provide further insight 
into disease state and activity in a personalized manner. In conclusion, this method 
may detect among disease specific antibodies those endowed with a pathogenic 
potential, but further studies on a group of well characterised RA patients will be 
necessary to verify the clinical significance of these findings. 
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Figure Legends 
Figure 1. U937 cells bind efficiently to human IgG1, IgG3 and IgG4, not IgG2.  
(A) IgG subclasses, coupled equally, detected with kappa chain specific antibody. (B) 
Representative sensogram of IgG subclasses detected with U937 cells. (C) Cell 
binding expressed as percentage of the highest signal in each cycle. Data in (A and 
C) shows the mean of three replicate runs with three spots per run.  Resonance Unit 
values shown were recorded in the last 10 seconds of the 15 minute incubation, 
marked with the dotted frame in (B).Bars represent means with error bars showing 
Standard Deviation. 
Figure 2. Comparison of NHS and RA sera reactivity towards IgG, MAPs, and 
subsequent recognition by U937 cells.  (A) Representative sensograms recorded 
for NHS and RA samples, on various ligands, showing phases of the measurement 
(depicted in (B)), with dashed frames indicating the response values evaluated. (C) 
Results of serum association measured on IgG1 and IgG3, and (D) MAPs: HCP2 and 
VCP2, and (E-F) the following cell binding response on these ligands are shown. 
Symbols in (C-F) mark the mean RU unit obtained on the ligand subtracted by PBS 
background. Statistical significance (C-F) was calculated by Mann-Whitney U test. 
(G) Comparison of serum and cell binding response on MAPs, here Spearman’s rank 
correlation coefficients (r) were calculated. 
Figure 3. Immunoglobulin levels against citrullinated peptides correlate with 
U937 responses in RA patients. (A) HCP2 and VCP2 specific IgA, IgG, IgM 
measured by microarrays and  (B) IgG subclasses as determined by ELISA from RA 
samples were compared to cell response values obtained from the biosensor 
experiments measured on the same antigens. Symbols represent the mean of 
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replicate measurements after subtraction of background values. Spearman's rank 
correlation coefficients (r) were calculated to evaluate the correlations.  
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    U937 cell response 
    VCP2 10 mM HCP2 1 mM 
    + - + - 
CCP2 
+ 11 2 5 8 
- 1 9 2 8 
    p=0.0006, *** p=0.4050, n.s. 
            
RA 
+ 12 6 7 11 
- 0 5 0 5 
    p=0.0137, * p=0.2719, n.s. 
Table 1. RA diagnosis and CCP2 positivity shows association with cellular 
response against VCP2. Diagnostic performance of cell binding response measured 
on MAPs after serum incubation with NHS or RA samples were compared to CCP2 
tests and RA diagnosis. Results are summarized as a contingency table, separately 
for comparison with CCP2 test and RA diagnosis results. To assess the associations 
Fisher's exact test was calculated. 
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Figure 1. U937 cells bind efficiently to human IgG1, IgG3 and IgG4, not IgG2.  (A) IgG subclasses, coupled 
equally, detected with kappa chain specific antibody. (B) Representative sensogram of IgG subclasses 
detected with U937 cells. (C) Cell binding expressed as percentage of the highest signal in each cycle. Data 
in (A and C) shows the mean of three replicate runs with three spots per run.  Resonance Unit values shown 
were recorded in the last 10 seconds of the 15 minute incubation, marked with the dotted frame in (B).Bars 
represent means with error bars showing Standard Deviation.  
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Figure 2. Comparison of NHS and RA sera reactivity towards IgG, MAPs, and subsequent recognition by 
U937 cells.  (A) Representative sensograms recorded for NHS and RA samples, on various ligands, showing 
phases of the measurement (depicted in (B)), with dashed frames indicating the response values evaluated. 
(C) Results of serum association measured on IgG1 and IgG3, and (D) MAPs: HCP2 and VCP2, and (E-F) the 
following cell binding response on these ligands are shown. Symbols in (C-F) mark the mean RU unit 
obtained on the ligand subtracted by PBS background. Statistical significance (C-F) was calculated by Mann-
Whitney U test. (G) Comparison of serum and cell binding response on MAPs, here Spearman’s rank 
correlation coefficients (r) were calculated.  
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Figure 3. Immunoglobulin levels against citrullinated peptides correlate with U937 responses in RA patients. 
(A) HCP2 and VCP2 specific IgA, IgG, IgM measured by microarrays and  (B) IgG subclasses as determined 
by ELISA from RA samples were compared to cell response values obtained from the biosensor experiments 
measured on the same antigens. Symbols represent the mean of replicate measurements after subtraction 
of background values. Spearman's rank correlation coefficients (r) were calculated to evaluate the 
correlations.  
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Supplementary Figure 1. Repeated 
measurements of hIgG1 and hIgG3 
with U937 cells. Cell adherence to 
triplicates of 100  nM spots of IgG1 and 
IgG3 was recorded in 22 cycles on the 
same sensor after each other. Each 
symbol shows results of a single 
measurement in a cycle, and bars mark 
the mean of the triplicates. Response 
expressed in Resonance Units (RU).
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Supplementary Figure 2. Correlation of antigen specific immunoglobulin levels 
with serum response on MAPs: HCP2 and VCP2. (A) Comparison of antigen specific 
antibody levels measured by antigen microarray for IgG, IgA and IgM and (B) by ELISA for 
IgG subclasses with serum association response on MAPs. Spearman's rank correlation 
coe1fficients (r) were considered significant as follows: * - p<0.05, ** - p<0.01 . n.s. - non 
significant. RU – response unit, RFI - Relative Fluorescent Intensity, AU - Arbitrary Unit
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Supplementary Table 1. Correlation of antigen 
speciﬁc IgG subclass levels of RA serum samples, 
measured on HCP2 and VCP2. Antigen speciﬁc 
IgG1-4 subclass levels were determined by ELISA. 
Spearman's rank correlation coeﬃcients(r) are 
shown in each cell with the row and column head-
ers indicating the compared subclasses for VCP2 in 
dark gray, and in light gray for HCP2. Correlations 
were considered signiﬁcant at p < 0.05.
VCP2 r = 0.60 r = 0.79 r = 0.69
p = 0.00864 p = 0.00011 p = 0.00138
r = 0.79 r = 0.64 r = 0.80
p = 0.00008 p = 0.00464 p = 0.00008
r = 0.86 r = 0.83 r = 0.60
p = 0.00001 p = 0.00002 p = 0.00825
r = 0.45 r = 0.60 r = 0.44
p = 0.06407 p = 0.00793 p = 0.07069 HCP2
IgG2
IgG3
IgG4
IgG1 IgG2 IgG3 IgG4
IgG1
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Supplementary Table 2. Correlation of antigen speciﬁc IgG, 
IgM and IgA levels of RA serum samples, measured on HCP2 
and VCP2. Antigen speciﬁc levels of IgA, IgG and IgM of the 
samples were determined by antigen microarray. Spearman's 
rank correlation coeﬃcients(r) are shown in each cell with the 
row and column headers indicating the compared isotypes for 
VCP2 in dark gray, and in light gray for HCP2. Correlations 
were considered signiﬁcant at p < 0.05.
VCP2 r = 0.75 r = 0.83
p = 0.00004 p < 0.00001
r = 0.72 r = 0.77
p = 0.00011 p = 0.00002
r = 0.89 r = 0.79
p < 0.00001 p = 0.00001 HCP2
IgM
IgG IgA IgM
IgG
IgA
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